REGENTIS BIOMATERIALS LTD.

Regentis Biomaterials Ltd. announced the pricing of a private placement of ordinary shares and warrants to accredited and institutional investors, expecting to raise approximately $6.5 million in gross proceeds. The funds will be used to advance its GelrinC pivotal clinical trial, prepare for FDA submission, develop its Gelrin technology platform, and support European market entry. The offering is expected to close on or about June 23, 2026.

Regentis Biomaterials Ltd. announced the withdrawal of its Form F-1 Registration Statement (File No. 333-295510), effective June 15, 2026. The company has decided not to proceed with the public offering to which the Registration Statement relates.

Regentis Biomaterials Ltd. filed an amendment to its registration statement detailing its policies on indemnification, exculpation, and insurance for its office holders, in accordance with Israeli law. The filing also outlines recent sales of unregistered securities, including various convertible and bridge loans that have been amended and, in some cases, converted into ordinary shares. These transactions involved significant amounts and included provisions for risk premiums and warrants tied to an initial public offering.

Regentis Biomaterials Ltd. announced plans to commence European surgeon training for its GelrinC product in the third quarter of 2026. This initiative accelerates preparations for the commercial rollout of GelrinC in Europe, where it already holds CE Mark approval. The training program, designed to provide practical experience with the 10-minute implantation procedure, will begin in Milan, Italy, and expand to other European markets. GelrinC is positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, targeting a significant market opportunity.

Regentis Biomaterials Ltd. has issued a Notice and Proxy Statement for its Annual General Meeting of Shareholders scheduled for July 2, 2026. The meeting agenda includes the re-election of directors, ratification of external director appointments, approval of stock option grants and warrant issuances to directors, adoption of a compensation policy, and the re-appointment of auditors. Shareholders of record as of June 9, 2026, are entitled to vote.

Regentis Biomaterials Ltd. announced its Annual General Meeting (AGM) of shareholders to be held on July 2, 2026, in Tel Aviv, Israel. The agenda includes the re-election of Dr. Ehud Geller and Mr. Efraim Cohen-Arazi to the Board of Directors, approval of option grants to serving directors and a top-up grant to Mr. Pini Ben-Elazar, and the issuance of warrants to Dr. Ehud Geller and Mr. Jeff Dykan. Additionally, shareholders will vote on the adoption of the Company's Compensation Policy and the re-appointment of Deloitte Israel & Co. as the independent auditors for the fiscal year ending December 31, 2026.

Regentis Biomaterials Ltd. filed an F-1 registration statement for a public offering of 3,333,334 ordinary shares at an assumed price of $3.00 per share, with an over-allotment option for 500,000 additional shares. The company provided updates on its GelrinC pivotal trial, having recruited 47 of 80 initial patients and expecting to complete recruitment by Q3 2026, aiming for PMA submission by the end of 2027. Additionally, Regentis announced key management changes, including a new CEO, CFO, and CMO, and a new collaboration with Humanitas Research Hospital in Europe.